DelveInsight’s, “Influenza Pipeline Insight, 2022,” report provides comprehensive insights about 120+ companies and 120+ pipeline drugs in Influenza pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Influenza Pipeline Insight Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Influenza collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Influenza Pipeline Insight Report
Request a sample and discover the recent advances in influenza treatment @ Influenza Pipeline Report
Influenza Overview
Influenza, one of the most common infectious diseases, is a highly contagious airborne disease that occurs in seasonal epidemics and manifests as an acute febrile illness with variable degrees of systemic symptoms, ranging from mild fatigue to respiratory failure and death. Influenza causes significant loss of workdays, human suffering, and mortality. The CDC documented that seasonal influenza was responsible for 24,000 to 62,000 deaths during the 2019-2020 season. Information used to generate influenza in-season burden estimates were too low during the 2020-2021 season to provide an estimate. Mortality was highest in infants and elderly persons. Influenza traditionally has been diagnosed on the basis of clinical criteria, but rapid diagnostic tests, which have a high degree of specificity but only moderate sensitivity, are becoming more widely used. The gold standard for diagnosing influenza A and B is a viral culture of nasopharyngeal samples or throat samples. In elderly or high-risk patients with pulmonary symptoms, perform chest radiography to exclude pneumonia. Prevention of influenza is the most effective management strategy. Influenza A and B vaccine is administered each year before flu season. The CDC analyzes the vaccine subtypes each year and makes any necessary changes for the coming season on the basis of worldwide trends. Traditionally, the vaccine was trivalent (ie, designed to provide protection against three viral subtypes, generally an A-H1, an A-H3, and a B). The first quadrivalent vaccines, which provide coverage against an additional influenza B subtype, were approved in 2012 and were made available for the 2013-2014 flu season. For the 2021-2022 influenza season, all flu vaccines are expected to be quadrivalent.
Recent Developmental Activities in the Influenza Pipeline
Influenza Emerging Drugs
Find out more about Influenza Medication tests @ Influenza Treatment Landscape
Influenza Pipeline Therapeutic Assessment
There are approx. 120+ key companies which are developing the therapies for Influenza. The companies which have their Influenza drug candidates in the most advanced stage, i.e. phase III include, Moderna.
Scope of the Influenza Pipeline Report
Dive deep into rich insights for drugs for influenza treatment, visit @ Influenza Vaccine
Table of Content
For further information on the influenza pipeline therapeutics, reach out @ Influenza Drugs
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/